Natera Inc. Common Stock vs ZIM Integrated Shipping Services Ltd — how do they compare? Natera Inc. Common Stock trades at $394.16 (market cap $57.03B), while ZIM Integrated Shipping Services Ltd trades at $29.84 (market cap $3.67B). The key difference: Natera Inc. Common Stock is far larger — about 15.5× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and ZIM Integrated Shipping Services Ltd for 23 Days on average.
| NTRA | ZIM | |
|---|---|---|
Market Cap | $57.03B | $3.67B |
Volume | 1,131,157 | 1,172,596 |
Sector | Health | Industrials |
52-Week High | $425.64 | $30.90 |
52-Week Low | $179.42 | $13.32 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $56.18B | $7.34B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
ZIM trades at $30.43, down 1.52% on the day, with a bullish technical signal from moving averages. The stock is near its 52-week high of $30.96, reflecting strong momentum. Fundamentally, Q2 2026 earnings of $0.53 per share significantly beat expectations, driven by a 9% revenue increase to $1.8 billion, though full-year 2026 guidance indicates margin pressure. The pending $35 per share acquisition offer from Hapag-Lloyd, subject to Israeli government approval, creates a key near-term catalyst.
The investment case balances potential upside from the acquisition against operational risks. If approved, the deal offers immediate premium; if rejected, ZIM's standalone value hinges on sustaining high transpacific freight rates. Analyst sentiment is cautious with no buy ratings, highlighting execution and geopolitical risks. The stock presents a speculative opportunity with binary outcomes centered on the merger decision.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →